This Friday, May 31, the FDA is hosting a public hearing to obtain scientific data and information regarding the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. The key goals of this hearing are to:
- Foster the development of appropriate hemp products under the 2018 Farm Bill, while also preserving FDA’s ability to protect the public health.
- Gather additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform FDA’s regulatory oversight of these products.
As part of the public hearing, the FDA is interested in whether there are particular safety concerns that the agency should be aware of as it considers the regulatory oversight and monitoring of cannabis-based products (including food, dietary supplements, therapeutic drugs). The results of the public hearing will help guide an FDA working group that will explore possible regulatory pathways for dietary supplements and/or foods containing CBD to be lawfully and safely marketed.
The agenda includes speakers from academia, agriculture, consumers, health care professionals, patients, manufacturers, and retailers/distributors, as well as state and government officials. The FDA will webcast this public hearing.
The FDA does not intend for this hearing to produce any decisions or new positions on regulatory questions, but it is expected to be an important step in the continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.
Want to receive the latest science and insights on cannabis use in your inbox? Subscribe for free!